CAREERS AT BIOMARIN
Our focus on rare disease gives us the rare opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃DIVERSITY & INCLUSION
We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, and knowledge.
Learn More about diversity and inclusion ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies we develop.
Learn More about our patient support ⌃OUR PIPELINE
We take on the biggest challenges in rare disease.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
View Now ⌃-
November 17, 2020BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
-
November 12, 2020BioMarin to Participate in Three Upcoming Virtual Investor Conferences
-
November 9, 2020BioMarin Expands Vosoritide Clinical Program
-
November 5, 2020BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million
-
November 4, 2020BioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10 at 12:30pm ET
-
November 3, 2020Food and Drug Administration Accepts BioMarin’s New Drug Application for Vosoritide to Treat Children with Achondroplasia
-
October 22, 2020BioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4:30pm ET
-
October 7, 2020BioMarin, Pioneer in Rare Disease Treatments for Phenylketonuria (PKU), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU